2026-10-21 · By SEPT AI
*By SEPT AI*
U.S. equities finished Wednesday's session with a modestly higher tilt, as strength in large-cap technology lifted the Nasdaq-100 while small caps lagged, leaving the major averages mixed but leaning positive. The session's tone was set early by a pair of divergent earnings reactions — a disappointing quarter from Netflix and an upbeat report from SpaceX — that kept investors selective rather than broadly aggressive.
The Invesco QQQ Trust closed at $725.20, up 0.41%, pacing the advance after trading in a range between $719.71 and $727.95. The SPDR S&P 500 ETF finished at $773.13, up 0.25%, having touched a high of $774.44 and a low of $768.40. The SPDR Dow Jones Industrial Average ETF edged higher to $527.70, a gain of 0.17%, after dipping as low as $523.15 intraday. Small caps were the outlier: the iShares Russell 2000 ETF slipped 0.14% to $276.48, spending the session between $275.30 and $277.70.
The Fear & Greed Index stood at 63, firmly in "greed" territory — a reading that suggests investors remain comfortable adding risk even as the day's leadership narrowed toward megacap technology.
The day's action was defined less by sector rotation than by stock-specific catalysts. Technology and semiconductor names drew support from Super Micro Computer's raised first-quarter sales guidance and Amkor Technology's $1.3 billion multi-year packaging agreement with Nvidia, both of which reinforced the appetite for AI-adjacent infrastructure. That helped the QQQ outpace the broader market.
Small caps, by contrast, could not hold their footing, with the Russell 2000 ETF finishing slightly red. The weakness came despite a generally constructive news flow, suggesting profit-taking rather than any single macro driver.
The most dramatic move of the session belonged to POM, which more than doubled, closing at $2.00 for a gain of 110.53% on volume of 27.3 million shares. SPHL surged 23.34% to $3.54 on heavy volume of 42.0 million shares, while PDSB climbed 22.22% to $1.22. HURA added 19.54% to close at $2.08, SDEV rose 17.02% to $1.10 on a striking 119.4 million shares traded, and TKNO gained 14.73% to $5.84.
On the downside, AMOD collapsed 45.36% to $1.03 on volume of 87.6 million shares — a striking reversal given the company's disclosure that its AMOD Tech unit holds more than $250 million in Bitcoin. NCPL fell 32.91% to $1.57, WORX dropped 31.83% to $2.42, and RCUS slid 21.95% to $19.10. GNLX lost 18.58% to $2.06, OLOX fell 18.32% to $1.01 on 52.9 million shares, and AVEX declined 16.91% to $9.68.
Among larger names, LAD dropped 16.80% to $269.13, RAPP fell 16.22% to $25.06, and GUTS lost 15.44% to $1.15. CYPH gained 12.12% to $3.33, SKYD rose 11.55% to $7.87 on 48.9 million shares, and ACCV added 11.53% to $13.93.
Key Earnings
Netflix weighed on sentiment after reporting third-quarter sales that missed analyst estimates, with full-year 2026 and fourth-quarter sales guidance both coming in below consensus. The results landed as a notable disappointment for one of the market's bellwether growth names.
SpaceX delivered the counterpoint, posting strong third-quarter results and issuing first-quarter 2027 sales guidance above expectations. Cantor Fitzgerald maintained an Overweight rating and raised its price target to $345 from $246.
Super Micro Computer lifted its first-quarter sales outlook above consensus, sending shares higher. Amkor Technology secured a $1.3 billion multi-year packaging arrangement in South Korea with Nvidia as counterparty.
In the broader earnings slate, Abbott Laboratories matched estimates with EPS of $1.42 and revenue of $13.01 billion, slightly ahead of the $12.99 billion consensus. CME Group earned $3.02 per share against a $2.99 estimate on revenue of $1.74 billion. CSX posted EPS of $0.57 versus $0.531 expected, with revenue of $4.02 billion topping the $3.96 billion estimate. CACI beat handily at $7.66 per share against a $6.57 estimate. On the misses, M/I Homes reported adjusted EPS of $2.70 against a $3.35 estimate, with revenue of $1.076 billion falling short of the $1.109 billion consensus. Winnebago guided fiscal 2027 GAAP EPS to $0.90–$1.50, below the $1.79 estimate. INVE Technologies cut its third-quarter sales outlook to $2.9–$3.1 million while guiding EPS of $0.01–$0.02.
No major economic releases or Federal Reserve commentary were reported in Wednesday's session. The market's direction was driven almost entirely by corporate news flow.
Ashford Hospitality Trust announced it would waive $17 million in advisory fees and terminate its at-the-market offering program, alongside a share purchase commitment — a move that signals insider-aligned capital discipline. INVE Technologies launched a buyback of up to $20 million in shares through a modified Dutch auction, with holders able to sell at prices from $2.85 to $3.40 per share in cash.
On the capital-raising side, TNL Mediagene sold $6.25 million in convertible preferred shares to Vector Advisory Partners in a private placement, while Helio filed an S-1 registration for a public offering ahead of a planned Nasdaq debut under the symbol HLEO.
Alpha Modus Holdings disclosed that its AMOD Tech unit holds more than $250 million worth of Bitcoin — a sizable treasury position for a company of its size. The disclosure did not prevent the stock from posting the session's steepest decline, with AMOD falling 45.36%. Separately, HeartSciences filed a definitive proxy for its proposed merger with Fortitude Mining, a Zcash miner, with shareholders set to vote on November 19.
Thursday's calendar brings a fresh wave of earnings, with investors watching for follow-through from the technology complex after Wednesday's split verdict on Netflix and SpaceX. The semiconductor supply chain remains in focus following Amkor's Nvidia pact and Super Micro's raised guidance. Traders will also monitor whether small caps can stabilize after Wednesday's underperformance, and whether the Fear & Greed Index's "greed" reading holds or cools. On the regulatory front, Unicycive Therapeutics' FDA acceptance of its NDA resubmission for oxylanthanum carbonate and BioCryst's clearance for an oral pellet form of ORLADEYO keep the biotech catalyst pipeline active, while Roivant's positive Phase 3 uveitis data for brepocitinib sets up a planned supplemental filing in the first half of 2027.
Access real-time market data, AI analysis, dark pool activity, and options flow.
Start Free Trial